Mylan Closes Merck KGaA Merger, Looks To Fill Remaining Pipeline Gaps
Executive Summary
Following the close of its acquisition of Merck KGaA's generics unit, Mylan is looking to round out its product portfolio with oncology and women's healthcare products
You may also be interested in...
Chief Executive Change At Teva Illustrates Diversification Emphasis At Major Generic Drug Makers
Most of the top 20 generic drug makers are subsidiaries of diversified pharmas or smaller generics-only plays based in the Far East. But diversification, although long a goal, is now urgent for the three major independent generic firms – Teva, Mylan and Watson.
Teva/Barr Merger Could Spell Opportunity For Smaller Generic Firms
Several generic firms are calling the pending merger of Teva and Barr a positive development for the rest of the industry, saying that it will leave behind ample market share for smaller companies
Teva/Barr Merger Could Spell Opportunity For Smaller Generic Firms
Several generic firms are calling the pending merger of Teva and Barr a positive development for the rest of the industry, saying that it will leave behind ample market share for smaller companies